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Sthat their therapy stays on track. These issues are likely to be
further magnified by an increasing number of patients un-
dergoing endoscopic therapy and continued economic chal-
lenges in medicine, particularly related to the poor
reimbursement for these procedures.
In conclusion, both endoscopic therapy and esophagec-
tomy are appropriate treatment options for patients with
high-grade dysplasia or intramucosal adenocarcinoma.
Although morbidity is increased with esophagectomy
compared with endotherapy, esophagectomy is generally
a 1-shot treatment. In contrast, the majority of patients un-
dergoing endoscopic therapy require multiple interventions
and remain at risk for cancer development until all the intes-
tinal metaplasia has been eradicated. Failure to aggressively
eradicate all Barrett’s tissue and carefully monitor these pa-
tients sets the stage for recurrent cancer, and could poten-
tially change a largely curable condition into a fatal
disease. Although endoscopic therapy has revolutionized
the therapy for high-grade dysplasia and intramucosal can-
cer, it is critical to not forget the lethality of this cancer and
get nonchalant in patients fortunate enough to be found with
a lesion that is nearly always curable.
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Dr Ross M. Bremner (Phoenix, Ariz). One year ago at this
meeting we discussed the optimal treatment of patients with
very early esophageal cancer at a breakfast meeting, referring of
course to patients with high-grade dysplasia and intramucosal car-
cinoma. Since these patients rarely, if ever, have the potential for
lymph node or metastatic spread, local therapies are probably ap-
propriate. Our experiences with the techniques of endoscopic re-
section and radiofrequency and cryoablation are relatively
limited. The work that we have heard this morning probably rep-
resents the largest US experience, and, although this is a retrospec-
tive review, I congratulate the authors on their impressive data and
a very thoughtful and well-written manuscript. I do have a couple
of questions.
One of the problems with embarking on an endoscopic protocol
is relying on the biopsy protocols that we do inasmuch as they in-
troduce a possible sampling error from the biopsy specimens. How
do we know that we have sampled adequately and can we be reas-
sured that we are not missing a more advanced cancer? In that re-
gard, is there any value for narrow-band imaging, vital dyes, and
perhaps high-frequency ultrasound to help our biopsy techniques?
Dr DeMeester. Yes, that is an important issue. I think narrow-
band imaging is probably useful. It is much easier than vital
sprays and dyes, which are fairly complicated, time consuming,
and a bit of a nuisance. The reality is, if you follow a Seattle pro-
tocol—4-quadrant biopsies every 1 to 2 cm throughout the length
of the columnar mucosa—you do not miss many lesions. You get at
least a feel for what is going on. I think it is less of an issue of miss-
ing high-grade dysplasia than actually the pathologist being
wrong, and it is important to have a good pathologist interpret
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invasive cancer that you do not know about? Multiple surgical se-
ries of esophagectomies have shown that almost 50% of the time
there will be an associated adenocarcinoma that has not been iden-
tified. However, a number of years ago John Nigro presented our
paper on that. If you have a high-grade dysplasia and a focus of
invasive cancer, in almost all cases the lesion is limited to the mu-
cosa. It would be rare to have an invisible lesion penetrating into
the submucosa, so you do not need to worry about that in general.
You can reliably ablate high-grade dysplasia and nonvisible
cancers with the techniques available today.
Dr Bremner. I agree that embarking on an endoscopic protocol
is pretty labor intensive inasmuch as it requires multiple therapies
and continued follow-up. Quite frankly, it is a little nerve-wracking
when you start doing this on otherwise healthy younger patients.
However, once cured, swallowing with one’s own esophagus is in-
tuitively better than swallowing with a gastric tube. Have you done
any long-term quality of life indices to help us understand this bet-
ter, or are you planning to do this once you have longer follow-up?
Dr DeMeester. That is an important issue, and I think we will
pursue that down the road. However, anecdotally there is no com-
parison, particularly in the case of a patient who can then undergo
a Nissen fundoplication. Regardless of how good the results are
with the gastric pull-up or an esophageal replacement, these pa-
tients have lifestyle modifications and reflux disease the rest of
their lives. They sleep with the head of their bed elevated, they
have to eat their evening meal early, because they are at constant
risk of regurgitation and aspiration, and that cannot be avoided. I
think it is going to end up very favorable for esophageal preserva-
tion, but it is a big issue in terms of the number of treatment
sessions necessary to get these patients to the point of having no
intestinal metaplasia.
Dr Bremner. That is quite relevant, especially with the younger
patients. There is going to be a paper discussed at this meeting re-
garding the incidence of Barrett’s esophagus in patients who have
had an esophagectomy in the proximal part of the esophagus. Most
of these patients with high-grade dysplasia are going to be cured
with an esophagectomy, but 10 to 20 years down the line, they
may still have a problem with Barrett’s esophagus.
Dr Robert Cerfolio (Birmingham, Ala). The follow-up of these
patients is the key thing to me. When you have a patient who has
a very low operative risk and you know you can probably get him
through it and cure him, deciding to do something that is ‘‘moreThe Journal of Thoracic and Cconservative’’ I would argue is less conservative. What follow-
up schedule do you use? What is the frequency, and do you use
endoscopic ultrasound routinely on your follow-up?
Dr DeMeester. No. Are you talking about an endoscopic
patient?
Dr Cerfolio. Yes.
Dr DeMeester.We do not use endoscopic ultrasound at all be-
cause it is worthless for these early lesions. The tumors have to get
deep into the submucosa or into the muscularis propria before they
can be reliably identified even with high-frequency ultrasound, so I
follow them up with routine endoscopies. They get an endoscopy
at 8 weeks after their ablative procedure and biopsies. If there is
any residual intestinal metaplasia or dysplasia, they are immedi-
ately scheduled for another ablative therapy, and that sequence
continues every 8 weeks until we get rid of all the intestinal
metaplasia.
We have learned the hard way. A few patients have had delays in
their follow-up and they have come back then with progression to
high-grade dysplasia or cancer.
Dr Cerfolio. That has been our problem as well and hence the
question. The compliance with follow-up is another issue that
needs to be considered initially as well. Let’s say they are doing
well and their intestinal metaplasia is gone. Is follow-up conducted
every 3 months, every 6 months, every year, or what?
DrDeMeester.Once all the intestinal metaplasia has been erad-
icated, then follow-up is conducted at 3 months, 6 months, and
then annually.
Dr Donald Low (Seattle, Wash). This is an important topic and
an evolving issue in surgery. I have 2 quick questions.
Endoscopic techniques are playing a larger and larger role in
virtually everything we do in the upper gastrointestinal tract.
Who is doing your interventional endoscopic procedures at the
University of Southern Califormia? Is it the surgeons or is it the
gastroenterologist?
The second question concerns assessment and decision-making.
We agree with you that treatment has to be individualized. Are all
your patients, especially those with intramucosal cancer, being
reviewed at your tumor boards?
Dr DeMeester. All these patients are treated by us as the
surgeons, and so we do all our own endoscopic procedures, our
own endoscopy follow-up, and so forth. There is no tumor
board review. We make the decision with the patient on which
way to go.ardiovascular Surgery c Volume 141, Number 1 47
